Although CD4+ T cells from RA patients often display reduced responsiveness to TGF-β1, they remain effectively modulated by tolDCs, highlighting their therapeutic promise supported by early-phase human RA data [111]. The gene discussed is CD4; the disease is rheumatoid arthritis.